The enhanced efficacy of dual inhibitors targeting EZH1 and EZH2, demonstrated by their superior ability to diminish cellular H3K27me3 levels and their heightened antitumor effects in murine models of hematologic malignancies compared to selective EZH2 inhibition, has led to clinical efficacy assessments.249. The gene discussed is EZH2; the disease is hematologic disorder.